|
|
Vaccine Detail
|
Telomerase Peptide Vaccine GV1001 |
| Vaccine Information |
- Vaccine Name: Telomerase Peptide Vaccine GV1001
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007169
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- mouse Trp53
gene engineering:
- Description: This is for Prostate Cancer (NCT02855892). A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with the telomerase peptide GV1001 may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells (Kim et al., 2016; NCIT_C62756).
|
| Host Response |
|
|
| References |
Kim et al., 2016: Kim H, Seo EH, Lee SH, Kim BJ. The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide. International journal of molecular sciences. 2016; 17(12); . [PubMed: 27941629].
NCIT_C62756: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756]
NCT02855892: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH [https://clinicaltrials.gov/ct2/show/NCT02855892]
Rivoltini et al., 1999: Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer research. 1999; 59(2); 301-306. [PubMed: 9927036].
|
|
